Clinical trials: Metastatic Solid Tumor Cancer
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma
- Trial name
- NCT02045602
- Testing
- VCN-01, Gemcitabine, Abraxane®
- Where
- 5 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Theriva Biologics SL
Homologous Recombination Deficient Solid Tumors
Niraparib and Dostarlimab in HRD Solid Tumors
This is an open-label, single-arm, Phase 2 study which will evaluate the efficacy and safety of niraparib and dostarlimab (TSR-042) combination in patients with metastatic, recurrent, or unresectable solid tumor with a…
- Trial name
- DIDO (NCT04983745)
- Testing
- Combination drug
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- West Cancer Center
Metastatic Cancer, Solid Tumors
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
The purpose of this study is to assess the safety and tolerability of ASP9801 and to determine the recommended phase 2 dose (RP2D).
- Conditions
- Metastatic Cancer, Solid Tumors, Advanced Cancer
- Trial name
- NCT03954067
- Testing
- ASP9801, Pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 72 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in…
- Conditions
- Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07262619
- Testing
- EIK1005, pembrolizumab (KEYTRUDA® )
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 160 people
- Sponsor
- Eikon Therapeutics
Non-small Cell Lung Cancer, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06612840
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Trial name
- NCT07462650
- Testing
- EB-DUO-CAR-NK-CEA/GCC (IV)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Unspecified Adult Solid Tumor, Protocol Specific
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00274859
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- 14 sites in France
- Volunteers
- 45 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00042874
- Testing
- alvocidib, irinotecan hydrochloride, fluorouracil
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN044 in participants with all advanced solid tumors who are not able to have current standard…
- Trial name
- NCT04126590
- Testing
- KN044
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Folic acid may protect normal cells from the side effects of chemotherapy and may increase the effectiveness…
- Trial name
- NCT00024310
- Testing
- folic acid, lometrexol, paclitaxel
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients…
- Conditions
- Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
- Trial name
- NCT04840589
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
The purpose of this clinical trial is to identify the highest dose of MEN1309 drug with acceptable safety profile and that can be used in patients affected by CD205-positive solid tumors and Non-Hodgkin Lymphoma
- Trial name
- CD205SHUTTLE (NCT03403725)
- Testing
- MEN1309
- Where
- 7 sites in Belgium, Italy and 2 more
- Volunteers
- 28 people
- Sponsor
- Menarini Group
Metastatic Cancer, HER2 Gene Mutation
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar)
- Trial name
- NCT06083662
- Testing
- Neratinib Maleate
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Korea University Guro Hospital
HER2-positive Solid Tumors
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
This is an open-label, phase II，multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.
- Trial name
- NCT04521179
- Testing
- KN026 combination
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Cancer of Colon, Malignant Melanoma
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
The purpose of this study is to evaluate the safety and efficacy of IVIG in the treatment of metastatic cancer of the prostate, colon and melanoma.
- Conditions
- Cancer of Colon, Malignant Melanoma, Urologic Cancer
- Trial name
- NCT00294476
- Testing
- IVIG, Biological Therapy
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- GammaCan
Breast Cancer, Lung Cancer
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma
- Trial name
- OCTANE (NCT02906943)
- Where
- 7 sites in Canada
- Volunteers
- 10,000 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.